CEL SCI CORP Logo

CEL SCI CORP

Develops immunotherapies for cancer, autoimmune, and infectious diseases.

CVM | US

Overview

Corporate Details

ISIN(s):
US1508377066
LEI:
Country:
United States of America
Address:
8229 BOONE BLVD ., 22182 VIENNA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CEL-SCI Corporation is a clinical-stage biotechnology company specializing in the research and development of immunotherapy products for the treatment of cancer, autoimmune diseases, and infectious diseases. The company's lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a pre-surgical treatment for advanced primary head and neck cancer. Its core therapeutic strategy is to activate the patient's immune system before standard treatments like surgery, chemotherapy, or radiation weaken it. A pivotal Phase III study showed Multikine provided a significant 5-year survival benefit. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) platform for autoimmune and infectious diseases, including a potential treatment for Rheumatoid Arthritis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CEL SCI CORP filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CEL SCI CORP

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CEL SCI CORP via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX
Protalix BioTherapeutics, Inc. Logo
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX

Talk to a Data Expert

Have a question? We'll get back to you promptly.